Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to the development and commercialisation of molecularly-targeted radiation (MTR) therapy. Our products seek to address major clinical unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
Our mission is
to help patients
with cancer live longer
with better quality lives
Once a year we like to put out a comprehensive summary of our programs and how they are progressing. If you'd like to see how molecular imaging and targeted radiotherapy will change cancer care - check it out!